As treatment options for patients with lymphoma rapidly evolve, Seattle Cancer Care Alliance’s (SCCA) physicians and researchers continue to be at the forefront of the latest scientific research, clinical trials and FDA-approved therapies. In fact, many of the options we offer are only available at SCCA. When considering the optimal treatments for your patients with lymphoma, you have a trusted partner in us.
Unique clinical trials for lymphoma only offered at SCCA
Lymphoma trials at SCCA include novel chemotherapy, biological and immunotherapeutic approaches, including CAR T-cell therapies. SCCA has one of the most active clinical trial programs in the world and remains a leader in investigator-initiated trials for nearly all lymphoma diagnoses.
Learn more at SeattleCCA.org/lymphoma-trials
Novel treatments, including FDA-approved CAR T-cell therapies Yescarta® and Kymriah®
Tisagenlecleucel, known by the brand name Kymriah,® and axicabtagene ciloleucel (axi-cel), known by the brand name Yescarta,® are recently FDA-approved CAR T-cell therapies available only at certified treatment centers. SCCA is one of the first in the nation to offer both for patients with relapsed or refractory aggressive non-Hodgkin lymphoma.
Learn more at SeattleCCA.org/car-t-faq
Expanded transplant options for patients with lymphoma
The Fred Hutch BMT Program at SCCA is a leader in offering treatment options to patients who may not be eligible at other centers. Our decades of experience allow us to transplant patients who are older (in their 70s) or have comorbidities, using approaches that include reduced-intensity preparative regimens. We also offer a variety of donor options — such as umbilical cord blood, HLA-mismatched and haploidentical donors, and a wide range of clinical trials — to provide treatment options for patients in need of a stem cell transplant.
Learn more at SeattleCCA.org/refer-transplant